Evidence map›Paper›PMID 32021174›Full record

ArticleInternational journal of nanomedicine2020

Consequences Of Long-Term Bacteria's Exposure To Silver Nanoformulations With Different PhysicoChemical Properties.

Anna Kędziora, Maciej Wernecki, Kamila Korzekwa, Mateusz Speruda, Yuriy Gerasymchuk, Anna Łukowiak, Gabriela Bugla-Płoskońska

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Review
  3. Gallium Resistance inApplied microbiology (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Dual Burst and Sustained Release ofACS applied materials & interfaces · 2023
    Article
  11. Benefits of Usage of Immobilized Silver Nanoparticles asInternational journal of molecular sciences · 2021
    Article
  12. Review
  13. Article
  14. Silver Nanoparticles and Their Antibacterial Applications.International journal of molecular sciences · 2021
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anna KędzioraDepartment of Microbiology, Institute of Genetics and Microbiology, University of Wroclaw, Wroclaw, Poland.ORCID 0000-0002-0947-1402
Maciej WerneckiDepartment of Microbiology, Institute of Genetics and Microbiology, University of Wroclaw, Wroclaw, Poland.ORCID 0000-0003-4821-5898
Kamila KorzekwaDepartment of Microbiology, Institute of Genetics and Microbiology, University of Wroclaw, Wroclaw, Poland.ORCID 0000-0002-2792-8752
Mateusz SperudaDepartment of Microbiology, Institute of Genetics and Microbiology, University of Wroclaw, Wroclaw, Poland.ORCID 0000-0001-6936-3633
Yuriy GerasymchukTrzebiatowski Institute of Low Temperature and Structure Research PAS in Wrocław, Wroclaw, Poland.ORCID 0000-0002-2148-672X
Anna ŁukowiakTrzebiatowski Institute of Low Temperature and Structure Research PAS in Wrocław, Wroclaw, Poland.ORCID 0000-0001-7511-5214
Gabriela Bugla-PłoskońskaDepartment of Microbiology, Institute of Genetics and Microbiology, University of Wroclaw, Wroclaw, Poland.ORCID 0000-0002-1222-201X
University of Wrocław · PLWłodzimierz Trzebiatowski Institute of Low Temperature and Structure Research · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeResistance to antibiotics is a major problem of public health. One of the alternative therapies is silver - more and more popular because of nanotechnology development and new possibilities of usage. As a component of colloid, powder, cream, bandages, etc., nanosilver is often recommended to treat the multidrug-resistant pathogens and we can observe its overuse also outside of the clinic where different physicochemical forms of silver nanoformulations (e.g. size, shape, compounds, surface area) are introduced. In this research, we described the consequences of long-term bacteria exposure to silver nanoformulations with different physicochemical properties, including changes in genome and changes of bacterial sensitivity to silver nanoformulations and/or antibiotics. Moreover, the prevalence of exogenous resistance to silver among multidrug-resistant bacteria was determined. MATERIALS AND

methodsGram-negative and Gram-positive bacteria strains are described as sensitive and multidrug-resistant strains. The sensitivity of the tested bacterial strains to antibiotics was carried out with disc diffusion methods. The sensitivity of bacteria to silver nanoformulations and development of bacterial resistance to silver nanoformulations has been verified via determination of the minimal inhibitory concentrations. The presence of

resultsBacteria after long-term exposure to silver nanoformulations may change their sensitivity to silver forms and/or antibiotics, depending on the physicochemical properties of silver nanoformulations, resulting from phenotypic or genetic changes in the bacterial cell. Finally, adaptants and mutants may become more sensitive or resistant to some antibiotics than wild types.

conclusionApplication of silver nanoformulations in the case of multiple resistance or multidrug-resistant bacterial infection can enhance or decrease their resistance to antibiotics. The usage of nanosilver in a clinic and outside of the clinic should be determined and should be under strong control. Moreover, each silver nanomaterial should be considered as a separate agent with a potential different mode of antibacterial action.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialGram-Negative BacteriaGram-Positive BacteriaMicrobial Sensitivity TestsNanostructuresSilverAnti-Bacterial AgentsSilveradaptantantibioticsmutantresistancesil genessilver

Identifiers

PMID32021174
PMCPMC6970275
OpenAlexW2999033781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.